Abstracts tagged "Biomarkers"

Abstract Number: 1475 • 2014 ACR/ARHP Annual Meeting
Porphyromonas Gingivalis and Bone Turnover Biomarkers in Rheumatoid Arthritis
Manpreet Sethi¹, Anand Dusad¹, Harlan Sayles², Geoffrey Thiele³, Jeffrey Payne⁴, Michael J. Duryee⁵, Bart Hamilton⁶ and Ted R. Mikuls⁷, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Int Med/Sec of Rheum/Immun, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Nebraska Medical Centre and Omaha VA Medical Center, Omaha, NE, ⁷Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Periodontitis (PD) associated with P. gingivalis has been implicated as a risk factor for rheumatoid arthritis (RA). We have previously demonstrated that RA patients…
Abstract Number: 982 • 2014 ACR/ARHP Annual Meeting
Identification of Potential SERUM Autoantibody Biomarkers in Rheumatic Diseases Using a New Generation of Protein Arrays
Lucia Lourido¹, Juan Fernandez-Tajes¹, Valentina Calamia¹, Carolina Fernandez-Costa^1,2, Beatriz Rocha¹, Patricia Fernandez-Puente¹, Jesus Mateos¹, Carlos Fernandez-Lopez¹, Natividad Oreiro-Villar¹, Manuel Fuentes³, Francisco J. Blanco Garcia¹ and Cristina Ruiz-Romero¹, ¹Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A coruña, Spain, ³Centro de Investigación del Cáncer/IBMCC (USAL/CIC), IBSAL, Departamento de Medicina, Unidad de Proteomica Servicio general de Citometría, Universidad de Salamanca, Salamanca, SPAIN., Salamanca, Spain
Background/Purpose Osteoarthritis (OA) is characterized by the loss of structural components from the extracelullar matrix (ECM) of articular cartilage. The progressive release of proteins from…
Abstract Number: 402 • 2014 ACR/ARHP Annual Meeting
Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?
Masao Sato^1,2, Masao Takemura^2,3, Kuniaki Saito⁴ and Yasuko Yamamoto⁴, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Matsunami Reserch Park, Gifu, Japan, ³Informative Laboratory Merdicine, Gifu University, Gifu, Japan, ⁴Human Health Science, Kyoto University, Kyoto, Japan
Background/Purpose GP88 (progranulin; PGRN), a glycoprotein with a molecular weight of approximately 88000, is suggested to play an important role in the immune response and…
Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 1964 • 2014 ACR/ARHP Annual Meeting
Changes in Soluble CD18 Reflect Latency in the Immune System and Predict Radiographic Progression in Early Rheumatoid Arthritis
Tue Wenzel Kragstrup¹, Babak Jalilian¹, Kresten Krarup Keller², Kristian Stengaard-Pedersen³, Merete Lund Hetland⁴, Kim Hørslev-Petersen⁵, Peter Junker⁶, Mikkel Østergaard⁴, Ellen Margrethe Hauge^7,8, Malene Hvid¹, Thomas Vorup-Jensen¹ and Bent Deleuran^1,3, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Glostrup University Hospital, Glostrup, Denmark, ⁵Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁶Odense University Hospital, Odense, Denmark, ⁷Dept. of Anatomi, Aarhus University, Aarhus, Denmark, ⁸Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose In early rheumatoid arthritis (RA), clinical disease characterized by swollen and painful joints is caused by synovitis. However, presence of autoantibodies may precede the…
Abstract Number: 1473 • 2014 ACR/ARHP Annual Meeting
Manocept-Cy3 Localizes CD206 + Macrophages in Synovial Tissue and Fluid from Rheumatoid Arthritis Patients Differentially Compared to Controls
Nicholas A. Young¹, Larry Schlesinger², Thomas J. Rosol³, Fred Cope⁴ and Wael N. Jarjour⁵, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Center for Microbial Interface Biology, Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, ³The Ohio State University College of Veterinary Medicine, Columbus, OH, ⁴Navidea Biopharmaceuticals, Dublin, OH, ⁵Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Early identification of rheumatoid arthritis (RA) would allow aggressive treatment with disease modifying rheumatic drugs and provide a system to monitor patient responses. Therefore,…
Abstract Number: 920 • 2014 ACR/ARHP Annual Meeting
Randomized Controlled Trial to Assess the Safety and Efficacy of Odanacatib in the Treatment of Men with Osteoporosis
Eric Orwoll¹, Silvano Adami², Neil Binkley³, Roland Chapurlat⁴, Bente Langdahl⁵, Steven Doleckyj⁶, Hilde Giezek⁷, Boyd Scott⁸ and Arthur Santora⁸, ¹Oregon Health and Science University, Portland, OR, ²Rheumatology Department, University of Verona, Verona, Italy, ³University of Wisconsin, Madison, WI, ⁴Pavillon F Rheumatology, Hopital Edouard Herriot, Lyon, France, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Belgium, Brussels, Belgium, ⁸Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose Osteoporosis in men is an important clinical problem, associated with significant morbidity, mortality and societal expense. Men with osteoporosis represent between 20 and 25%…
Abstract Number: 400 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of 14-3-3η in the Evaluation of Inflammatory Arthritis
Lance Feller¹, Paul Tuttle IV² and Terry L. Moore³, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Rheumatology, Saint Louis University, Saint Louis, MO, ³Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting
Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Priyanka Vashisht¹, Jessica M. Dorschner², Mark A. Jensen³, Beverly Chrabot⁴, Theresa Wampler Muskardin⁵, Marlena Kern⁶, Tetrad Investigators⁷, ABCoN Consortium⁸, S. Louis Bridges Jr.^9,10, P.K. Gregersen¹¹ and Timothy B. Niewold², ¹Division of Rheumatology and Department of Immunology, University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁶North Shore Univ Hospital, Feinstein Institute for Medical Research, Manhasset, NY, ⁷AL, ⁸NY, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹¹The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA). Previous studies have suggested that circulating type I interferon (IFN)…
Abstract Number: 1921 • 2014 ACR/ARHP Annual Meeting
The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus
Joan T. Merrill¹, Aikaterini Thanou², Stan Kamp¹, John Conklin³, Derren Barken⁴ and Thierry Dervieux⁵, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: We sought to evaluate the usefulness of cell bound complement activation products (C4d deposition on erythrocytes [EC4d] and platelets [PC4d]) in the monitoring of…
Abstract Number: 1462 • 2014 ACR/ARHP Annual Meeting
Cadherin-11 mRNA Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis
Petros P. Sfikakis¹, Panagiotis F. Christopoulos^1,2, Aristeidis G. Vaiopoulos^1,2, Kalliopi Fragkiadaki¹, Christina Katsiari³, Violetta Kapsimali⁴, George Lallas¹, Panayiotis Panayiotidis⁴, Pinelopi Korkopoulou⁵ and Michael Koutsilieris², ¹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²Department of Physiology, Athens University Medical School, Athens, Greece, ³Department of Rheumatology, School of Health Sciences, University of Thessaly, Larissa, Greece, ⁴Department of Microbiology, Athens University Medical School, Athens, Greece, ⁵Department of Pathology, Athens University Medical School, Athens, Greece
Background/Purpose: Human rheumatoid arthritis synovial fibroblasts (RASF) implanted subcutaneously in immunodeficient mice trans-migrate through the vasculature and drive the progression from oligo- to poly-articular disease.…
Abstract Number: 914 • 2014 ACR/ARHP Annual Meeting
A Predictive Model of Disease Outcome in Rituximab-Treated Myositis Patients Using Clinical Features, Autoantibodies, and Serum Biomarkers
Jeannette Olazagasti¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla¹, Rohit Aggarwal³, Chester V. Oddis⁴ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Develop predictive models of early (8 week) and late (24 week) disease outcomes using clinical features, autoantibodies, and serum biomarkers in patients with refractory…
Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting
Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Jérémie Sellam¹, Houria Chavez², Stéphanie Rouanet³, Nathalie Vernet³, Bineta Ly⁴, Sandrine Marion-Thore⁵, Bernard Combe⁶, Jean Sibilia⁷, Jacques Tebib⁸, Gilles Chiocchia⁹, Maxime Dougados¹⁰, Yassine Taoufik² and Xavier Mariette¹¹, ¹AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Biostatistics, Roche France, Boulogne-Billancourt, France, ⁴INSERM U1012, Universite Paris-Sud, Kremlin Bicetre, France, ⁵INSERM U1016, Université Versailles Saint-Quentin, Montigny le Bretonneux, France, ⁶Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸Rheumatology, University Hospital Lyon, Lyon, France, ⁹Université Versailles-Saint Quentin, Montigny le Bretonneux, France, ¹⁰INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ¹¹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose . The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].